Neoadjuvant endocrine therapy often leads to breast and axilla‐conserving surgery in stages II and III hormone receptor‐positive breast cancer patients: A registry study

Documenti analoghi

• The Predictive Value of the Tumor‐Stroma Ratio for Neoadjuvant Endocrine Therapy in Hormone Receptor‐Positive Breast Cancer
  di: Layla Andour, et al.
  Pubblicazione: (2026)
• Worse health quality outcomes found with endocrine therapy after breast‐conserving surgery
  di: Mary Beth Nierengarten
  Pubblicazione: (2025)
• Primary angiosarcoma of the breast with metastasis to the ovary and axilla: an uncommon pattern of metastatic disease
  di: Jorge Cea García
  Pubblicazione: (2016)
• A prospective study on accuracy of methylene blue dye guided low axillary sampling in staging of axilla in breast cancer
  di: Dr. Shradha Tamang1, Dr. Navneet Kaur2
  Pubblicazione: (2025)
• Reprogramming innate immunity to overcome endocrine resistance in estrogen receptor‐positive breast cancer
  di: Siti Nur Hasyila Muhammad, et al.
  Pubblicazione: (2026)